论文部分内容阅读
目的:探讨氨溴特罗治疗早产儿呼吸窘迫综合征(RDS)的临床疗效。方法:66例早产RDS患儿,随机分为观察组和对照组各33例,对照组予常规治疗,观察组在常规治疗基础上加用氨溴特罗雾化吸入,3～4 d为一疗程。治疗后测定纠正胎龄37周时患儿肺功能并评定疗效。结果:观察组总有效率为90.9%,明显高于对照组的69.7%(P<0.05);观察组治愈患儿的住院天数为(14.9±4.3)d,亦明显低于对照组的(19.2±4.8)d(P<0.05);观察组患儿肺功能指标Tptef/Te虽低于正常组,但明显较对照组高(P<0.05)。结论:雾化吸入氨溴特罗治疗早产儿RDS疗效较好。
Objective: To investigate the clinical efficacy of ambroxol in the treatment of respiratory distress syndrome (RDS) in preterm infants. Methods: Sixty-six premature infants with RDS were randomly divided into observation group (33 cases) and control group (n = 33). The control group was given routine treatment. The observation group received inhalation of ambroxol on the basis of conventional treatment. Course of treatment. After treatment to determine the correction of gestational age at 37 weeks of children with pulmonary function and assess the efficacy. Results: The total effective rate in the observation group was 90.9%, significantly higher than that in the control group (69.7%, P <0.05). The hospitalization days in the observation group were (14.9 ± 4.3) d and were significantly lower than those in the control group (19.2 ± 4.8) d (P <0.05). The pulmonary function index Tptef / Te in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Inhaled inhalation of ambroxol is effective in treating premature infants with RDS.